JP2007523183A - 縮合複素環式化合物及び代謝調節型グルタミン酸受容体アンタゴニストとしてのその使用 - Google Patents

縮合複素環式化合物及び代謝調節型グルタミン酸受容体アンタゴニストとしてのその使用 Download PDF

Info

Publication number
JP2007523183A
JP2007523183A JP2006554237A JP2006554237A JP2007523183A JP 2007523183 A JP2007523183 A JP 2007523183A JP 2006554237 A JP2006554237 A JP 2006554237A JP 2006554237 A JP2006554237 A JP 2006554237A JP 2007523183 A JP2007523183 A JP 2007523183A
Authority
JP
Japan
Prior art keywords
alkyl
triazolo
oxadiazol
tetrahydro
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006554237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007523183A5 (https=
Inventor
ヨハンソン，マーティン
ウェンスボ，デービッド
ミニディス，アレクサンダー
スターフ，カリン
カーズ，アニカ
エドワーズ，ルイス
アイザック，メスヴィン
ステファナック，トミスラブ
スラッシ，アブデルマリック
マックレオド，ドナルド
ジン，タオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Shire NPS Pharmaceuticals Inc
Original Assignee
AstraZeneca AB
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB, NPS Pharmaceuticals Inc filed Critical AstraZeneca AB
Publication of JP2007523183A publication Critical patent/JP2007523183A/ja
Publication of JP2007523183A5 publication Critical patent/JP2007523183A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2006554237A 2004-02-18 2005-02-17 縮合複素環式化合物及び代謝調節型グルタミン酸受容体アンタゴニストとしてのその使用 Withdrawn JP2007523183A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54528804P 2004-02-18 2004-02-18
US54558004P 2004-02-19 2004-02-19
PCT/US2005/005218 WO2005080397A2 (en) 2004-02-18 2005-02-17 Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders

Publications (2)

Publication Number Publication Date
JP2007523183A true JP2007523183A (ja) 2007-08-16
JP2007523183A5 JP2007523183A5 (https=) 2008-03-27

Family

ID=34886171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006554237A Withdrawn JP2007523183A (ja) 2004-02-18 2005-02-17 縮合複素環式化合物及び代謝調節型グルタミン酸受容体アンタゴニストとしてのその使用

Country Status (21)

Country Link
US (1) US20070185095A1 (https=)
EP (1) EP1716152B1 (https=)
JP (1) JP2007523183A (https=)
KR (1) KR20070026380A (https=)
CN (1) CN1934112A (https=)
AT (1) ATE402935T1 (https=)
BR (1) BRPI0507495A (https=)
CA (1) CA2556320A1 (https=)
DE (1) DE602005008558D1 (https=)
DK (1) DK1716152T3 (https=)
ES (1) ES2309718T3 (https=)
HR (1) HRP20080480T3 (https=)
IL (1) IL177291A0 (https=)
MY (1) MY152888A (https=)
PL (1) PL1716152T3 (https=)
PT (1) PT1716152E (https=)
RU (1) RU2006129324A (https=)
SI (1) SI1716152T1 (https=)
UA (1) UA82435C2 (https=)
WO (1) WO2005080397A2 (https=)
ZA (1) ZA200606508B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515777A (ja) * 2009-12-29 2013-05-09 イーライ リリー アンド カンパニー 統合失調症の処置に有用な選択的ｍＧｌｕ５受容体増強因子としてのテトラヒドロトリアゾロピリジン化合物
JP2016525111A (ja) * 2013-07-17 2016-08-22 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ４‐（３‐シアノフェニル）‐６‐ピリジニルピリミジンｍｇｌｕ５修飾剤

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200811179A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators VI
TW200808800A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
EP2119719A1 (en) * 2006-12-26 2009-11-18 Daiichi Sankyo Company, Limited Thiazepine derivative
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
WO2009054792A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Aminopyridine derivatives as modulators of mglur5
TW200922586A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054789A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
WO2009054786A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
PL2552920T3 (pl) 2010-04-02 2017-08-31 Ogeda Sa Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3
CA2795218A1 (en) * 2010-04-30 2011-11-03 Helen Blade Polymorphs of a metabotropic glutamate receptor positive allosteric modulator
DK2763992T3 (en) * 2011-10-03 2016-04-25 Euroscreen Sa NOVEL CHIRAL N-acyl-5,6,7, (8-substituted) -tetrahydro [1,2,4] triazolo [4,3-a] pyrazines as selective NK-3 receptor antagonists, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE use in the NK-3 receptor mediated diseases
US10183948B2 (en) 2013-03-29 2019-01-22 Ogeda Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
JP6275241B2 (ja) 2013-03-29 2018-02-07 オゲダ エス．エー． 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−５，６，７，８−テトラヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法
CA2907814C (en) 2013-03-29 2021-07-13 Euroscreen Sa Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
SG11201508005XA (en) 2013-03-29 2015-10-29 Euroscreen Sa NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
WO2016046398A1 (en) 2014-09-25 2016-03-31 Euroscreen Sa Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100875222B1 (ko) * 1999-08-19 2008-12-19 아스트라제네카 아베 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
US7074809B2 (en) * 2002-08-09 2006-07-11 Astrazeneca Ab Compounds

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515777A (ja) * 2009-12-29 2013-05-09 イーライ リリー アンド カンパニー 統合失調症の処置に有用な選択的ｍＧｌｕ５受容体増強因子としてのテトラヒドロトリアゾロピリジン化合物
JP2016525111A (ja) * 2013-07-17 2016-08-22 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ４‐（３‐シアノフェニル）‐６‐ピリジニルピリミジンｍｇｌｕ５修飾剤
US11584732B2 (en) 2013-07-17 2023-02-21 Heptares Therapeutics Limited Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators
US11680053B2 (en) 2013-07-17 2023-06-20 Heptares Therapeutics Limited Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators
US12415795B2 (en) 2013-07-17 2025-09-16 Nxera Pharma Uk Limited 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

Also Published As

Publication number Publication date
HRP20080480T3 (hr) 2008-11-30
EP1716152B1 (en) 2008-07-30
BRPI0507495A (pt) 2007-07-10
ES2309718T3 (es) 2008-12-16
HK1098460A1 (en) 2007-07-20
CN1934112A (zh) 2007-03-21
US20070185095A1 (en) 2007-08-09
WO2005080397A3 (en) 2005-12-22
UA82435C2 (uk) 2008-04-10
IL177291A0 (en) 2006-12-10
WO2005080397A8 (en) 2006-06-22
SI1716152T1 (sl) 2008-12-31
KR20070026380A (ko) 2007-03-08
RU2006129324A (ru) 2008-04-10
MY152888A (en) 2014-11-28
CA2556320A1 (en) 2005-09-01
ATE402935T1 (de) 2008-08-15
EP1716152A2 (en) 2006-11-02
PT1716152E (pt) 2008-10-02
WO2005080397A2 (en) 2005-09-01
PL1716152T3 (pl) 2009-01-30
ZA200606508B (en) 2007-11-28
DK1716152T3 (da) 2008-11-03
DE602005008558D1 (de) 2008-09-11

Similar Documents

Publication Publication Date Title
EP1716152B1 (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
JP4912157B2 (ja) 追加の複素多環式化合物及びそれらの代謝調節型グルタミン酸受容体アンタゴニストとしての使用
AU2007303889B2 (en) mGluR5 modulators
RU2381226C2 (ru) Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
JP2009536213A (ja) 縮合複素環化合物及びｍｇｌｕｒ５モジュレーターとしてのその使用
US20060019997A1 (en) Triazole compounds and their use as metabotropic glutamate receptor antagonists
EP2163554B1 (en) Pyrimidodiazepinone derivative
JP2009536214A (ja) 縮合複素環化合物及びｍｇｌｕｒ５モジュレーターとしてのその使用
US20080312246A1 (en) Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists
AU2008317544A1 (en) Amino 1,2,4-triazole derivatives as modulators of mGluR5
US7576077B2 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
HK1098460B (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
MXPA06009018A (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
MXPA06009021A (en) Triazole compounds and their use as metabotropic glutamate receptor antagonists
MXPA06009020A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080204

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090827